Advances in Hematology
Volume 2019 (2019), Article ID 4120631, 2 pages
https://doi.org/10.1155/2019/4120631

Corrigendum

Corrigendum to “Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update”

Paola Villafuerte-Gutierrez,¹ Lucia Villalon,² Juan E. Losa,³ and Cesar Henriquez-Camacho³

¹Hospital Universitario Torrejón de Ardoz, Servicio de Hematología, Calle Mateo Inurria, 28850 Madrid, Spain
²Hospital Universitario Fundación Alcorcón, Servicio de Hematología, Calle Budapest 1, 28922 Madrid, Spain
³Unidad de Medicina Interna, Sección de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Calle Budapest 1, 28922 Madrid, Spain

Correspondence should be addressed to Cesar Henriquez-Camacho; doctorcesarhenriquez@gmail.com

Received 24 June 2019; Accepted 27 June 2019; Published 16 July 2019

Copyright © 2019 Paola Villafuerte-Gutierrez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The article titled “Treatment of Febrile Neutropenia and Prophylaxis in Hematologic Malignancies: A Critical Review and Update” [1] was found to contain material from previously published work. The articles are as follows:

(i) Freifeld, A. G., E. J. Bow, K. A. Sepkowitz, M. J. Boeckh, J. I. Ito, C. A. Mullen, I. I. Raad, K. V. Rolston, J.-A. H. Young, and J. R. Wingard. “Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America”, Clinical Infectious Diseases, 2011. https://doi.org/10.1093/cid/cir073. [2] (Cited as reference )

(ii) J. Gea-Banacloche, “Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies,” Hematology/the Education Program of the American Society of Hematology, vol. 2013, no. 1, pp. 414–422, 2013. [3] (Cited as reference )

(iii) Amar Safdar, “Principles and Practice of Cancer Infectious Diseases,” 2011. https://doi.org/10.1007/978-1-60761-644-3. [4] (Not cited)

(iv) Aarti S. Bhardwaj & Shyamala C. Navada (2013) Management of Chemotherapy-Induced Neutropenic Fever, Hospital Practice, 41:1, 96-108, DOI: 10.3810/hp.2013.02.1015. [5] (Not cited)

(v) L. Pagano, M. Caira, A. Nosari et al., “The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart project,” Haematologica, vol. 96, no. 9, pp. 1366–1370, 2011. Doi:10.3324/haematol.2011.042598. [6] (Cited as reference )

The article [1] includes an overlap of 437 words with Freifeld, A. G. et al. [2], 405 words with J. Gea-Banacloche et al. [3], 342 words with Amar Safdar et al. [4], 252 words with Aarti S. Bhardwaj et al. [5], and 221 words with L. Pagano et al. [6].

The authors said they did not intend to copy the work of others, but this occurred because some phrases are difficult to rephrase and no new knowledge was presented in this article. The authors apologized for this matter.

References

P. Villafuerte-Gutierrez, L. Villalon, J. E. Losa, and C. Henriquez-Camacho, “Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: A critical review and update,” Advances in Hematology, vol. 2014, Article ID 986938, 9 pages, 2014.

A. G. Freifeld, E. J. Bow, K. A. Sepkowitz et al., “Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, vol. 52, no. 4, pp. 427–431, 2011.

J. Gea-Banacloche, “Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies,” Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, vol. 2013, pp. 414–422, 2013.

A. Safdar, Principles and Practice of Cancer Infectious Diseases, 2011.

A. S. Bhardwaj and S. C. Navada, “Management of chemotherapy-induced neutropenic fever,” Hospital Practice, vol. 41, no. 1, pp. 96–108, 2015.

L. Pagano, M. Caira, A. Nosari et al., “The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart project,” Haematologica, vol. 96, no. 9, pp. 1366–1370, 2011.